Sale

Meningococcal Vaccines Market

Global Meningococcal Vaccines Market Share, Price, Report: By Type: Mono Vaccines, Combination Vaccines; By Age Group: Infants, Childrens, Adults; By Brand: Menactra, Menveo, Nimenrix, Trumenba, Bexsero, Others; By End User: Hospitals, Homecare, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Meningococcal Vaccines Market Outlook

The global meningococcal vaccines market stood at 172 million doses in 2020. The global meningococcal vaccines market is expected to grow at a healthy pace in the forecast period of 2024-2032.

 

Global Meningococcal Vaccines Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Prevalence of Meningococcal Meningitis to Aid the Market Growth of Meningococcal Vaccines

The market growth of meningococcal vaccines is being driven by the rising prevalence of various types of bacteria that trigger meningococcal meningitis. The most common among them are A, B, C, W, Y, and type X that was lately tracked in Africa. This is aiding the market growth of meningococcal vaccines as the demand for effective meningococcal vaccines is on the rise over the forecast period. The market is further being propelled by the extremely unpredictable dissemination of this bacteria and fluctuating occurrences of the disease over time and across different age groups and geographies, which has resulted in a considerable increase in the frequency of clinical programmes for the development of efficient meningococcal vaccines worldwide. Moreover, several ongoing clinical programmes for the development of meningococcal vaccines at varying stages is further facilitating the market growth globally.

 

Meningococcal Vaccines: Market Segmentation

Meningococcal meningitis is a rare and potentially disturbing bacterial infection that affects the brain. Even after the advances in the medical field, the disease has the potential to take the life of the host in a relatively lesser timespan. Meningococcal vaccines are produced as the prevention of meningococcal meningitis.

 

Global Meningococcal Vaccines Market By Age Group

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

On the basis of type, the market is divided into:

  • Polysaccharide Vaccine (MPSV4)
  • Conjugate Vaccine (MCV4)
  • Serogroup B Vaccine (MenB-FHpb/MenB-4C)

Based on age group, the industry can be segmented into:

  • Infants
  • Children
  • Adults
  • Others

By distribution channel, the industry is categorised into:

  • Institutional Sales
  • Retail Sales

These segments are further divided on the basis of type. Institutional sales are divided into hospitals, community clinics, and public health agencies, whereas retail sales are divided into retail pharmacy and online, among others.

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Meningococcal Vaccines Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Initiatives by the Government to Aid the Market Growth of Meningococcal Vaccines

The market growth of meningococcal vaccines is being driven by the rising initiatives like National Immunization Programs (NIPs) by the governments and supported by private non-profit organisations for the development of meningococcal vaccines. Further, the addition of meningococcal vaccines to NIPs with the motive to ascertain vaccine supply affordability and sustainability in public and private sectors has been generating an abundance of opportunities for the manufacturers.

 

Key Industry Players in the Global Meningococcal Vaccines Market

The report gives a detailed analysis of the following key players in the global meningococcal vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Incepta Vaccine Ltd. 
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Age Group
  • Brand
  • End User
  • Distribution Channel
  • Region
Breakup by Type
  • Mono Vaccines
  • Combination Vaccines
Breakup by Age Group
  • Infants
  • Childrens
  • Adults
Breakup by Brand
  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero
  • Others
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Johnson & Johnson Private Limited
  • Mylan N.V.
  • Sun Pharmaceutical Industries Limited
  • Sanofi S.A.
  • Merck & Co., Inc.
  • GSK plc.
  • Novartis AG
  • AbbVie Inc.
  • Fresenius Kabi AG
  • Amneal Pharmaceuticals LLC.
  • Pfizer Inc.
  • Serum Institute of India Pvt. Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Meningococcal Vaccines Market Overview 

    3.1    Global Meningococcal Vaccines Market Historical Value (2017-2023) 
    3.2    Global Meningococcal Vaccines Market Forecast Value (2024-2032)
4    Global Meningococcal Vaccines Market Landscape
    4.1    Global Meningococcal Vaccines Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Meningococcal Vaccines Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by End User
        4.2.3    Analysis by Major Regions
5    Global Meningococcal Vaccines Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Meningococcal Vaccines Market Segmentation 
    6.1    Global Meningococcal Vaccines Market by Type
        6.1.1    Market Overview
        6.1.2    Mono Vaccines
        6.1.3    Combination Vaccines
    6.2    Global Meningococcal Vaccines Market by Age Group
        6.2.1    Market Overview
        6.2.2    Infants
        6.2.3    Childrens
        6.2.4    Adults
    6.3    Global Meningococcal Vaccines Market by Brand
        6.3.1    Market Overview
        6.3.2    Menactra
        6.3.3    Menveo
        6.3.4    Nimenrix
        6.3.5    Trumenba
        6.3.6    Bexsero
        6.3.7    Others
    6.4    Global Meningococcal Vaccines Market by End User
        6.4.1    Market Overview
        6.4.2    Hospitals 
        6.4.3    Homecare
        6.4.4    Specialty Clinics
        6.4.5    Others
    6.5    Global Meningococcal Vaccines Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacy
        6.5.3    Online Pharmacy
        6.5.4    Retail Pharmacy
        6.5.5    Others
    6.6    Global Meningococcal Vaccines Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Meningococcal Vaccines Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Meningococcal Vaccines Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Meningococcal Vaccines Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Meningococcal Vaccines Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Meningococcal Vaccines Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Johnson & Johnson Private Limited
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Mylan N.V.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Sun Pharmaceutical Industries Limited
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Sanofi S.A.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Merck & Co., Inc.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    GSK plc.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Novartis AG
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    AbbVie Inc.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Fresenius Kabi AG
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Amneal Pharmaceuticals LLC.
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Pfizer Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Serum Institute of India Pvt. Ltd.
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Incepta Pharmaceuticals Ltd.
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Walvax Biotechnology Co., Ltd.
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Bio-Manguinhos
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
18    Global Meningococcal Vaccines Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2020, the global meningococcal vaccines market attained 172 million doses.

The major drivers of the industry, such as rising disposable incomes, increasing population, rising prevalence of the disease, and increasing demand for effective meningococcal vaccines, are expected to aid the market growth.

The key market trend guiding the growth of the industry includes the rise in the initiatives undertaken by the government.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading types of meningococcal vaccines in the market are polysaccharide vaccine (MPSV4), conjugate vaccine (MCV4), and serogroup B vaccine (MenB-FHpb/MenB-4C).

The major age groups considered in the market report are infants, children, and adults, among others.

The significant distribution channels in the industry are institutional sales and retail sales.

The major players in the industry are Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others.

Analyst Review

The global meningococcal vaccines market attained 172 million doses in 2020, driven by rising prevalence of urinary incontinence among the growing geriatric population. Aided by the technological advancements, the market is expected to witness a healthy growth in the forecast period of 2024-2032.
 
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the market is segmented into polysaccharide vaccine (MPSV4), conjugate vaccine (MCV4), and serogroup B vaccine (MenB-FHpb/MenB-4C). By age group, the industry is divided into infants, children, and adults, among others. On the basis of distribution channel, the market is segmented into institutional sales and retail sales. The major regional markets for meningococcal vaccines are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER